The Latest Breaking News from GSK

Pfizer is also facing off with collaborators Sanofi and AstraZeneca Plc to develop prevention for dangerous RSV infections in newborns, a market that could reach $1.5 billion.

WASHINGTON — Pfizer Inc.’s vaccine for respiratory syncytial virus received endorsement from a key panel of U.S. advisers for its safety in people 60 and older, a key endorsement for the drugmaker’s potential product.

"I wasn’t aware of what I had; I looked in the mirror, I had no idea what I was looking at except this hideously blistered face"

"When you look at the factors for both of us, we had both gone through stressful experiences, your bereavement, me a court case..."

You might not have heard of respiratory syncytial virus, or RSV. But it caused more than 100,000 global deaths in 2019, making it a leading cause of death in children under one year old.

Hybrid and flexible working is offered at most FTSE 100 companies, survey results suggest

Here is the full list of respondents and their feedback to a Evening Standard survey looking at weekly working patterns, writes Joanna Hodgson

A glitch in a law may make it difficult for children from low-income families to get the new RSV vaccine

Unite chiefs say their members are determined to get 'what they are owed' in bonus payments row.

The pharmaceutical industry is well-positioned for significant growth in the near future, given the growing demand for medicines and increasing R&D activities. Given the industry's inelastic demand, fundamentally strong pharma stocks AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and GSK plc (GSK) might be solid long-term investments. Continue reading….

Emma Walmsley says ambition to be pharma superpower at risk unless improvements made in key areas